Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 17Gastrointestinal 11Head & Neck 6Tumor-Agnostic 4Other solid neoplasm 4Genitourinary 4Dermatologic 3Lymphoid 2Gynecologic 2CNS 2Breast 2Sarcoma 1Plasma cell 1

Conditions

Solid Tumors 1Solid Tumor, Adult 1PD-L1-selected Solid Tumors 1Advanced Rare Malignant Solid Neoplasm 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Tiragolumab × Other solid neoplasm × Clear all
NCT05661578 2026-02-09

SKYSCRAPER-11

Hoffmann-La Roche

Phase 2 Completed
64 enrolled
Other solid neoplasm

PD-L1-selected Solid Tumors

NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
12 enrolled
Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

NCT06331598 2024-12-24

IMperator

Hoffmann-La Roche

Phase 2 Withdrawn
Other solid neoplasm

Solid Tumors

NCT06003621 2024-11-15

MoST-TAP

Omico

Phase 2 Recruiting
96 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡